HomeComparePSPTX vs ABBV

PSPTX vs ABBV: Dividend Comparison 2026

PSPTX yields 18.06% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $37.5K in total portfolio value· pulled ahead in Year 8
10 years
PSPTX
PSPTX
● Live price
18.06%
Share price
$11.99
Annual div
$2.17
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.8K
Annual income
$5,448.25
Full PSPTX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PSPTX vs ABBV

📍 ABBV pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSPTXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSPTX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSPTX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSPTX
Annual income on $10K today (after 15% tax)
$1,535.22/yr
After 10yr DRIP, annual income (after tax)
$4,631.01/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $16,424.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSPTX + ABBV for your $10,000?

PSPTX: 50%ABBV: 50%
100% ABBV50/50100% PSPTX
Portfolio after 10yr
$83.6K
Annual income
$15,110.00/yr
Blended yield
18.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PSPTX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSPTX buys
0
ABBV buys
0
No recent congressional trades found for PSPTX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSPTXABBV
Forward yield18.06%3.06%
Annual dividend / share$2.17$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$64.8K$102.3K
Annual income after 10y$5,448.25$24,771.77
Total dividends collected$34.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSPTX vs ABBV ($10,000, DRIP)

YearPSPTX PortfolioPSPTX Income/yrABBV PortfolioABBV Income/yrGap
1$12,506$1,806.14$11,550$430.00+$956.00PSPTX
2$15,493$2,111.01$13,472$627.96+$2.0KPSPTX
3$19,021$2,444.03$15,906$926.08+$3.1KPSPTX
4$23,157$2,804.37$19,071$1,382.55+$4.1KPSPTX
5$27,969$3,190.78$23,302$2,095.81+$4.7KPSPTX
6$33,528$3,601.68$29,150$3,237.93+$4.4KPSPTX
7$39,910$4,035.14$37,536$5,121.41+$2.4KPSPTX
8← crossover$47,193$4,489.00$50,079$8,338.38$2.9KABBV
9$55,457$4,960.88$69,753$14,065.80$14.3KABBV
10$64,788$5,448.25$102,337$24,771.77$37.5KABBV

PSPTX vs ABBV: Complete Analysis 2026

PSPTXStock

The investment seeks total return which exceeds that of the S&P 500 Index. The fund seeks to exceed the total return of the S&P 500 Index by investing under normal circumstances in S&P 500 Index derivatives, backed by a portfolio of fixed income instruments. "Fixed income instruments" include bonds, debt securities and other similar instruments issued by various U.S. and non-U.S. public- or private-sector entities. The fund will normally limit its foreign currency exposure (from non-U.S. dollar-denominated securities or currencies) to 35% of its total assets.

Full PSPTX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PSPTX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSPTX vs SCHDPSPTX vs JEPIPSPTX vs OPSPTX vs KOPSPTX vs MAINPSPTX vs JNJPSPTX vs MRKPSPTX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.